Professor Michael Eccles

Developmental Genetics Group, Dunedin School of Medicine, New Zealand Institute for Cancer Research Trust Chair in Cancer Pathology

Mike (NZICRT Chair in Cancer Pathology in the Pathology Department) heads the Developmental Genetics Group, which aims to identify key developmental mechanisms associated with cancer and differentiation/de-differentiation of cells in human disease. Mike has experience with various model systems and approaches to address the above, particularly investigations of kidney cancer, developmental gene families involved in kidney morphogenesis, and the control of gene expression affecting cell fate.

Recent Publications

Chen, Y.J., Eccles, M. et al. PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Research 68, 5724-5732 (2008).

Frost, V., Grocott, T., Eccles, M.R. & Chantry, A. Self-Regulated Pax Gene Expression and Modulation by the TGF beta Superfamily. Critical Reviews in Biochemistry and Molecular Biology 43, 371-391 (2008).

Hueber, P.A., Iglesias, D., Chu, L.L., Eccles, M. & Goodyer, P. In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Letters 265, 148-155 (2008).

Stayner, C., Eccles, M. et al. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease (vol 15, pg 3520, 2006). Human Molecular Genetics 18, 1543-1543 (2009).